What's hot
View all perspectives
There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.
Janet Pope Janetbirdope
1 year 3 months ago
Summary of #EULAR2024 #ClinicalPearls
JAKi have expanding disease data
✅ #GCA w #UPA
✅ Awaiting data in #SLE w #UPA & #Deucravacitinib
✅Use in #JIA
✅No new safety signals
@rheumnow
@eular_org
It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.
Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2024: New drugs for RA?
Abiprubart is an Abatacept distant relative, targeting T cell activation through a different target/molecular interaction (CD40/CD154).
https://t.co/3wAGjfCdcN https://t.co/2YK2OeIVZK
Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2024 - Day 1 Report
https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8
Dr. John Cush RheumNow
1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb & UCB. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.
Janet Pope Janetbirdope
1 year 3 months ago
How many #autoantibodies
Does one need in
#rheumatoid #arthritis
Need 4 citrullinated peptides
Covers off
97% of IgG CVP2 ACPAs
#EULAR2024 @RheumNow @eular_org https://t.co/LNFGuFXGrC
Janet Pope Janetbirdope
1 year 3 months ago
Once in remission with
#rituximab in #GPA
How long to resize
500 mg q6 mo for
4 years?
?longer
?less
#EULAR2024 @eular_org @RheumNow https://t.co/G4kU3v81je
Poster Hall